Hoth Therapeutics, Inc.
HOTH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,633 | $1,040 | $1,959 | $1,319 |
| G&A Expenses | $0 | $1,160 | $1,504 | $1,051 |
| SG&A Expenses | $2,447 | $1,160 | $1,517 | $1,064 |
| Sales & Mktg Exp. | $0 | $0 | $13 | $13 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,081 | $2,200 | $3,476 | $2,383 |
| Operating Income | -$4,081 | -$2,200 | -$3,476 | -$2,383 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$25 | $0 | $0 | $0 |
| Pre-Tax Income | -$4,106 | -$2,199 | -$3,476 | -$2,383 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,106 | -$2,199 | -$3,476 | -$2,383 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.17 | -0.36 | -0.33 |
| % Growth | -76.5% | 52.8% | -9.1% | – |
| EPS Diluted | -0.3 | -0.17 | -0.36 | -0.33 |
| Weighted Avg Shares Out | 13,787 | 13,180 | 9,778 | 7,290 |
| Weighted Avg Shares Out Dil | 13,787 | 13,180 | 9,778 | 7,290 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $3,476 | $2,383 |
| EBITDA | -$4,106 | -$2,199 | $0 | $0 |
| % Margin | – | – | – | – |